Altered microbial bile acid metabolism exacerbates t cell-driven inflammation during graft-versus-host disease

ABSTRACT Microbial transformation of bile acids affects intestinal immune homoeostasis but its impact on inflammatory pathologies remains largely unknown. Using a mouse model of

graft-versus-host disease (GVHD), we found that T cell-driven inflammation decreased the abundance of microbiome-encoded bile salt hydrolase (BSH) genes and reduced the levels of

unconjugated and microbe-derived bile acids. Several microbe-derived bile acids attenuated farnesoid X receptor (FXR) activation, suggesting that loss of these metabolites during

inflammation may increase FXR activity and exacerbate the course of disease. Indeed, mortality increased with pharmacological activation of FXR and decreased with its genetic ablation in

donor T cells during mouse GVHD. Furthermore, patients with GVHD after allogeneic hematopoietic cell transplantation showed similar loss of BSH and the associated reduction in unconjugated

and microbe-derived bile acids. In addition, the FXR antagonist ursodeoxycholic acid reduced the proliferation of human T cells and was associated with a lower risk of GVHD-related mortality

in patients. We propose that dysbiosis and loss of microbe-derived bile acids during inflammation may be an important mechanism to amplify T cell-mediated diseases. Access through your

institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio

journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 digital issues and online access to articles

$119.00 per year only $9.92 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are

calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS

IL-22-DEPENDENT DYSBIOSIS AND MONONUCLEAR PHAGOCYTE DEPLETION CONTRIBUTE TO STEROID-RESISTANT GUT GRAFT-VERSUS-HOST DISEASE IN MICE Article Open access 05 February 2021 FECAL TRANSPLANTATION

ALLEVIATES ACUTE LIVER INJURY IN MICE THROUGH REGULATING TREG/TH17 CYTOKINES BALANCE Article Open access 15 January 2021 RATIONALLY DESIGNED BACTERIAL CONSORTIA TO TREAT CHRONIC

IMMUNE-MEDIATED COLITIS AND RESTORE INTESTINAL HOMEOSTASIS Article Open access 28 May 2021 DATA AVAILABILITY Metabolomics data including standards (Figs. 1, 4 and 5, and Extended Data Figs.

4–7 and Tables 4 and 5) are available at GNPS (https://gnps.ucsd.edu/) under MassIVE project ID #MSV000092300. The bulk RNA-seq data from murine experiments (Fig. 2 and Extended Data Fig. 2)

are available at NCBI GEO under GEO accession GSE218343 and also in Supplementary tables. The 16S and shotgun sequencing data (Figs. 2 and 5, and Extended Data Fig. 7) are available at NCBI

under accession numbers listed in the Supplementary tables. The processed scRNA-seq files are available under GEO accession GSE253360. For access to raw data, kindly request permission by

contacting the contributing author at [email protected]. Please anticipate a response within 2 weeks. Once legal agreements are approved, raw genomic data can be shared within an

additional month. Source data for Figs. 1–3 and 6a–c, and for Extended Data Figs. 1–3 and 8 are available in the Supplementary tables. The datasets required to run the code were also made

publicly available in GitHub and are also included in the Supplementary information. Our institutional data-sharing policies prevent us from publicly posting the patient-level information

used to calculate clinical outcomes (Fig. 6t,u). However, interested parties may request access by contacting the contributing author at [email protected]. Please anticipate a response

within one month. Data sharing of patient-level information is contingent upon the establishment of a formal data transfer agreement between Memorial Sloan Kettering and the respective

parties involved. Source data are provided with this paper. CODE AVAILABILITY The code and the corresponding figures for Figs. 2d,e, 4, 5 and 6h–v, and for Extended Data Figs. 4–7 and 10 can

be accessed in GitHub (https://github.com/orianamiltiadous/BAs_and_GVHD). REFERENCES * Hamilton, J. P. et al. Human cecal bile acids: concentration and spectrum. _Am. J. Physiol.

Gastrointest. Liver Physiol._ 293, G256–G263 (2007). Article  CAS  PubMed  Google Scholar  * Chen, M. L., Takeda, K. & Sundrud, M. S. Emerging roles of bile acids in mucosal immunity and

inflammation. _Mucosal Immunol._ 12, 851–861 (2019). Article  CAS  PubMed  Google Scholar  * Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. _Cell_ 157,

121–141 (2014). Article  CAS  PubMed Central  PubMed  Google Scholar  * Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. _Annu. Rev. Biochem._ 72, 137–174 (2003).

Article  CAS  PubMed  Google Scholar  * Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. _J. Lipid Res._ 47, 241–259 (2006).

Article  CAS  PubMed  Google Scholar  * Begley, M., Hill, C. & Gahan, C. G. Bile salt hydrolase activity in probiotics. _Appl. Environ. Microbiol._ 72, 1729–1738 (2006). Article  ADS 

CAS  PubMed Central  PubMed  Google Scholar  * Wells, J. E. & Hylemon, P. B. Identification and characterization of a bile acid 7alpha-dehydroxylation operon in _Clostridium_ sp. strain

TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces. _Appl. Environ. Microbiol._ 66, 1107–1113 (2000). Article  ADS  CAS  PubMed Central  PubMed  Google Scholar 

* Devlin, A. S. & Fischbach, M. A. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. _Nat. Chem. Biol._ 11, 685–690 (2015). Article  CAS  PubMed Central 

PubMed  Google Scholar  * Quinn, R. A. et al. Global chemical effects of the microbiome include new bile-acid conjugations. _Nature_ 579, 123–129 (2020). Article  ADS  CAS  PubMed Central 

PubMed  Google Scholar  * Foley, M. H. et al. Bile salt hydrolases shape the bile acid landscape and restrict _Clostridioides difficile_ growth in the murine gut. _Nat. Microbiol._ 8,

611–628 (2023). Article  CAS  PubMed Central  PubMed  Google Scholar  * Patterson, A. et al. Bile acids are substrates for amine n-acyl transferase activity by bile salt hydrolase. Preprint

at _Res. Square_ https://doi.org/10.21203/rs.3.rs-2050120/v1 (2022). * Shin, D. J. & Wang, L. Bile acid-activated receptors: a review on FXR and other nuclear receptors. _Handb. Exp.

Pharmacol._ 256, 51–72 (2019). Article  CAS  PubMed  Google Scholar  * Hang, S. et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. _Nature_ 576, 143–148 (2019).

Article  ADS  CAS  PubMed Central  PubMed  Google Scholar  * Paik, D. et al. Human gut bacteria produce Τ(Η)17-modulating bile acid metabolites. _Nature_ 603, 907–912 (2022). Article  ADS 

CAS  PubMed Central  PubMed  Google Scholar  * Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. _Nature_ 581, 475–479 (2020).

Article  ADS  CAS  PubMed Central  PubMed  Google Scholar  * Gratwohl, A. et al. Hematopoietic stem cell transplantation: a global perspective. _JAMA_ 303, 1617–1624 (2010). Article  CAS 

PubMed Central  PubMed  Google Scholar  * Gooley, T. A. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. _N. Engl. J. Med._ 363, 2091–2101 (2010). Article  CAS 

PubMed Central  PubMed  Google Scholar  * Aljurf, M. et al. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor

registries. _Bone Marrow Transpl._ 54, 1179–1188 (2019). Article  Google Scholar  * Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation.

_N. Engl. J. Med._ 382, 822–834 (2020). Article  CAS  PubMed Central  PubMed  Google Scholar  * Taur, Y. et al. The effects of intestinal tract bacterial diversity on mortality following

allogeneic hematopoietic stem cell transplantation. _Blood_ 124, 1174–1182 (2014). Article  CAS  PubMed Central  PubMed  Google Scholar  * Jenq, R. R. et al. Regulation of intestinal

inflammation by microbiota following allogeneic bone marrow transplantation. _J. Exp. Med._ 209, 903–911 (2012). Article  CAS  PubMed Central  PubMed  Google Scholar  * Holler, E. et al.

Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced

in gastrointestinal graft-versus-host disease. _Biol. Blood Marrow Transpl._ 20, 640–645 (2014). Article  Google Scholar  * Burgos da Silva, M. et al. Preservation of fecal microbiome is

associated with reduced severity of graft-versus-host disease. _Blood_ 140, 2385–2397 (2022). * Taur, Y. et al. Intestinal domination and the risk of bacteremia in patients undergoing

allogeneic hematopoietic stem cell transplantation. _Clin. Infect. Dis._ 55, 905–914 (2012). Article  CAS  PubMed Central  PubMed  Google Scholar  * Ara, T. & Hashimoto, D. Novel

insights into the mechanism of GVHD-induced tissue damage. _Front. Immunol._ 12, 713631 (2021). Article  CAS  PubMed Central  PubMed  Google Scholar  * Zeiser, R. & Blazar, B. R. Acute

graft-versus-host disease – biologic process, prevention, and therapy. _N. Engl. J. Med._ 377, 2167–2179 (2017). Article  CAS  PubMed Central  PubMed  Google Scholar  * Malard, F., Holler,

E., Sandmaier, B. M., Huang, H. & Mohty, M. Acute graft-versus-host disease. _Nat. Rev. Dis. Prim._ 9, 27 (2023). Article  PubMed  Google Scholar  * Reddy, P., Negrin, R. & Hill, G.

R. Mouse models of bone marrow transplantation. _Biol. Blood Marrow Transpl._ 14, 129–135 (2008). Article  Google Scholar  * Palmer, R. H. The formation of bile acid sulfates: a new pathway

of bile acid metabolism in humans. _Proc. Natl Acad. Sci. USA_ 58, 1047–1050 (1967). Article  ADS  CAS  PubMed Central  PubMed  Google Scholar  * Subramanian, A. et al. Gene set enrichment

analysis: a knowledge-based approach for interpreting genome-wide expression profiles. _Proc. Natl Acad. Sci. USA_ 102, 15545–15550 (2005). Article  ADS  CAS  PubMed Central  PubMed  Google

Scholar  * Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. _Nat. Genet._ 34, 267–273 (2003). Article

  CAS  PubMed  Google Scholar  * Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. _Gut_ 60,

463–472 (2011). Article  CAS  PubMed  Google Scholar  * Campbell, C. et al. FXR mediates T cell-intrinsic responses to reduced feeding during infection. _Proc. Natl Acad. Sci. USA_ 117,

33446–33454 (2020). Article  ADS  CAS  PubMed Central  PubMed  Google Scholar  * Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of

tauro-beta-muricholic acid, a naturally occurring FXR antagonist. _Cell Metab._ 17, 225–235 (2013). Article  MathSciNet  CAS  PubMed  Google Scholar  * Shono, Y. et al. Increased

GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. _Sci. Transl. Med._ 8, 339ra371 (2016). Article

  ADS  Google Scholar  * Ruutu, T. et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. _Blood_ 100, 1977–1983 (2002). Article 

CAS  PubMed  Google Scholar  * Ruutu, T. et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study.

_Biol. Blood Marrow Transpl._ 20, 135–138 (2014). Article  CAS  Google Scholar  * Guzior, D. V. & Quinn, R. A. Review: microbial transformations of human bile acids. _Microbiome_ 9, 140

(2021). Article  CAS  PubMed Central  PubMed  Google Scholar  * Claudel, T., Staels, B. & Kuipers, F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose

metabolism. _Arterioscler Thromb. Vasc. Biol._ 25, 2020–2030 (2005). Article  CAS  PubMed  Google Scholar  * Cox, D. R. Regression models and life-tables. _J. R. Stat. Soc. B_ 34, 187–202

(1972). MathSciNet  Google Scholar  * Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. _Theory Method_ 94, 496–509 (1997). * Haring, E.

et al. Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect. _Haematologica_ 106, 2131–2146 (2021).

Article  CAS  PubMed  Google Scholar  * Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. _Cell Host Microbe_ 15, 382–392 (2014). Article  CAS  PubMed Central 

PubMed  Google Scholar  * Peled, J. U. et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. _J. Clin. Oncol._ 35, 1650–1659 (2017). Article  PubMed Central 

PubMed  Google Scholar  * McCarville, J. L., Chen, G. Y., Cuevas, V. D., Troha, K. & Ayres, J. S. Microbiota metabolites in health and disease. _Annu. Rev. Immunol._ 38, 147–170 (2020).

Article  CAS  PubMed  Google Scholar  * Yao, L. et al. A selective gut bacterial bile salt hydrolase alters host metabolism. _Elife_ 7, e37182 (2018). Article  PubMed Central  PubMed  Google

Scholar  * Zhang, Y. et al. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation. _Br. J. Pharmacol._ 176, 2848–2863 (2019). Article  CAS  PubMed Central  PubMed  Google

Scholar  * Winston, J. A., Rivera, A., Cai, J., Patterson, A. D. & Theriot, C. M. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in

conventional mice. _PLoS ONE_ 16, e0246161 (2021). Article  CAS  PubMed Central  PubMed  Google Scholar  * Song, X. et al. Microbial bile acid metabolites modulate gut RORγ(+) regulatory T

cell homeostasis. _Nature_ 577, 410–415 (2020). Article  CAS  PubMed  Google Scholar  * Li, W. et al. A bacterial bile acid metabolite modulates T(reg) activity through the nuclear hormone

receptor NR4A1. _Cell Host Microbe_ 29, 1366–1377.e9 (2021). * Lee, J. W. J. et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel

disease. _Cell Host Microbe_ 29, 1294–1304.e4 (2021). Article  CAS  PubMed Central  PubMed  Google Scholar  * Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1

immunotherapy in melanoma patients. _Science_ 359, 97–103 (2018). Article  ADS  CAS  PubMed  Google Scholar  * Smith, M. et al. Gut microbiome correlates of response and toxicity following

anti-CD19 CAR T cell therapy. _Nat. Med._ 28, 713–723 (2022). Article  CAS  PubMed Central  PubMed  Google Scholar  * Stein-Thoeringer, C. K. et al. Lactose drives _Enterococcus_ expansion

to promote graft-versus-host disease. _Science_ 366, 1143–1149 (2019). Article  ADS  CAS  PubMed Central  PubMed  Google Scholar  * Mathewson, N. D. et al. Gut microbiome-derived metabolites

modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. _Nat. Immunol._ 17, 505–513 (2016). Article  CAS  PubMed Central  PubMed  Google Scholar  * Ritchie, M. E.

et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. _Nucleic Acids Res._ 43, e47 (2015). Article  PubMed Central  PubMed  Google Scholar  *

Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. _J. R. Stat. Soc. B_ 57, 289–300 (1995). MathSciNet  Google

Scholar  * Andrews, S. FastQC v.0.11.9 (Babraham Bioinformatics, 2015). * Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. _Bioinformatics_ 29, 15–21 (2013). Article  CAS  PubMed

  Google Scholar  * Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. _Bioinformatics_ 30, 923–930

(2014). * Peled, J. U., Gomes, A. L. C. & van den Brink, M. R. M. Microbiota and allogeneic hematopoietic-cell transplantation. Reply. _N. Engl. J. Med._ 382, 2378–2379 (2020). Article 

PubMed  Google Scholar  * Miltiadous, O. et al. Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. _Blood_ 139, 2758–2769

(2022). Article  CAS  PubMed Central  PubMed  Google Scholar  * Callahan, B. J., McMurdie, P. J. & Holmes, S. P. Exact sequence variants should replace operational taxonomic units in

marker-gene data analysis. _ISME J._ 11, 2639–2643 (2017). Article  PubMed Central  PubMed  Google Scholar  * Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina

amplicon data. _Nat. Methods_ 13, 581–583 (2016). Article  CAS  PubMed Central  PubMed  Google Scholar  * Dubin, K. A. et al. Diversification and evolution of vancomycin-resistant

_Enterococcus faecium_ during intestinal domination. _Infect. Immun._ 87, e00102–e00119 (2019). Article  CAS  PubMed Central  PubMed  Google Scholar  * Beghini, F. et al. Integrating

taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. _Elife_ 10, e65088 (2021). Article  CAS  PubMed Central  PubMed  Google Scholar  *

Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. _Nat. Methods_ 12, 59–60 (2015). Article  CAS  PubMed  Google Scholar  * Buchfink, B., Reuter, K.

& Drost, H. G. Sensitive protein alignments at tree-of-life scale using DIAMOND. _Nat. Methods_ 18, 366–368 (2021). Article  CAS  PubMed Central  PubMed  Google Scholar  * Menzel, P.,

Ng, K. L. & Krogh, A. Fast and sensitive taxonomic classification for metagenomics with Kaiju. _Nat. Commun._ 7, 11257 (2016). Article  ADS  CAS  PubMed Central  PubMed  Google Scholar 

* Stoeckius, M. et al. Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. _Genome Biol._ 19, 224 (2018). Article  CAS  PubMed Central

  PubMed  Google Scholar  * Lun, A. T. L. et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. _Genome Biol._ 20, 63 (2019). Article

  PubMed Central  PubMed  Google Scholar  * Kousa, A. I. & Lemarquis, A. The shunPykeR’s guide to single cell analysis (v.1.0.0). _GitHub_

https://github.com/kousaa/shunPykeR?tab=readme-ov-file (2023). * Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. _Sci. Rep._

9, 5233 (2019). Article  ADS  CAS  PubMed Central  PubMed  Google Scholar  * Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in

single-cell transcriptomic data. _Cell Syst._ 8, 281–291.e9 (2019). Article  CAS  PubMed Central  PubMed  Google Scholar  * Korsunsky, I. et al. Fast, sensitive and accurate integration of

single-cell data with Harmony. _Nat. Methods_ 16, 1289–1296 (2019). Article  CAS  PubMed Central  PubMed  Google Scholar  * Ntranos, V., Yi, L., Melsted, P. & Pachter, L. A

discriminative learning approach to differential expression analysis for single-cell RNA-seq. _Nat. Methods_ 16, 163–166 (2019). Article  CAS  PubMed  Google Scholar  Download references

ACKNOWLEDGEMENTS We acknowledge R. Chaligne, the single-cell analytics innovation laboratory (SAIL), the Integrated Genomics Operation Core (IGO) and the molecular microbiology facility

(MMF), which performed RNA sequencing (SAIL, IGO), as well as the 16S and metagenomic shotgun sequencing (MMF, IGO) for mouse and human studies. This research is funded by the National

Cancer Institute (NCI) Cancer Center Support Grant (CCSG, P30 CA08748), Cycle for Survival, and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology NCI award numbers

R01-CA228358, R01-CA228308, P30 CA008748 MSK Cancer Center Support Grant/Core Grant and P01-CA023766; National Heart, Lung and Blood Institute (NHLBI) award number R01-HL123340 and

R01-HL147584; and the Tri Institutional Stem Cell Initiative. Additional funding was received from The Lymphoma Foundation, The Susan and Peter Solomon Family Fund, The Solomon Microbiome

Nutrition and Cancer Program, Cycle for Survival, Parker Institute for Cancer Immunotherapy, Paula and Rodger Riney Multiple Myeloma Research Initiative, Starr Cancer Consortium, and Seres

Therapeutics. S.L. was supported by the Deutsche Forschungsgemeinschaft (DFG, LI 3565/1-1) and DKMS. O.M. was supported by the American Society of Clinical Oncology Young Investigator Award,

a Hyundai Hope on Wheels Young Investigator Award, a Cycle for Survival Equinox Innovation Award, a Collaborative Pediatric Cancer Research Program Award, a Michael Goldberg Fellowship and

a Tow Center for Developmental Oncology Career Development Award. K.A.M. was supported by the DKMS and the ASH Scholar Award. J.U.P. reports funding from NHLBI NIH Award K08HL143189. AUTHOR

INFORMATION Author notes * These authors contributed equally: Sarah Lindner, Oriana Miltiadous. AUTHORS AND AFFILIATIONS * Department of Immunology, Sloan Kettering Institute, Memorial Sloan

Kettering Cancer Center, New York, NY, USA Sarah Lindner, Jenny Paredes, Anastasia I. Kousa, Anqi Dai, Nicholas R. Waters, Keimya Sadeghi, Gabriel K. Armijo, Romina Ghale, Kristen Victor, 

Brianna Gipson, Chi L. Nguyen, John Slingerland, Hana Andrlova, Marina Burgos da Silva & Marcel R. M. van den Brink * Department of Pediatrics, Memorial Sloan Kettering Cancer Center,

New York, NY, USA Oriana Miltiadous * Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA Ruben J. F. Ramos & Justin R.

Cross * Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA Teng Fei * Transplantation and Cell Therapy Program, University of Michigan

Rogel Cancer Center, Ann Arbor, MI, USA Emma Lauder & Pavan Reddy * Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA John

Frame & Ying Taur * Center of Comparative Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA Sebastien Monette * Gene Editing and Screening Core Facility,

Memorial Sloan Kettering Cancer Center, New York, NY, USA Marco Vincenzo Russo * Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA Marco

Vincenzo Russo * Division of Medical Oncology, University of Washington, Seattle, WA, USA Kate A. Markey * Fred Hutchinson Cancer Center, Seattle, WA, USA Kate A. Markey * Adult Bone Marrow

Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Sergio Giralt, Miguel-Angel Perales, Jonathan U. Peled & Marcel R. M. van den

Brink * Department of Medicine, Weill Cornell Medical College, New York, NY, USA Sergio Giralt, Miguel-Angel Perales, Jonathan U. Peled & Marcel R. M. van den Brink * Division of Blood

and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA Melody Smith * CeMM Research Center for Molecular Medicine

of the Austrian Academy of Sciences, Vienna, Austria Clarissa Campbell * Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles,

CA, USA Marcel R. M. van den Brink * Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA, USA Marcel R. M. van den Brink * Comprehensive Cancer

Center, City of Hope, Los Angeles, CA, USA Marcel R. M. van den Brink Authors * Sarah Lindner View author publications You can also search for this author inPubMed Google Scholar * Oriana

Miltiadous View author publications You can also search for this author inPubMed Google Scholar * Ruben J. F. Ramos View author publications You can also search for this author inPubMed 

Google Scholar * Jenny Paredes View author publications You can also search for this author inPubMed Google Scholar * Anastasia I. Kousa View author publications You can also search for this

author inPubMed Google Scholar * Anqi Dai View author publications You can also search for this author inPubMed Google Scholar * Teng Fei View author publications You can also search for

this author inPubMed Google Scholar * Emma Lauder View author publications You can also search for this author inPubMed Google Scholar * John Frame View author publications You can also

search for this author inPubMed Google Scholar * Nicholas R. Waters View author publications You can also search for this author inPubMed Google Scholar * Keimya Sadeghi View author

publications You can also search for this author inPubMed Google Scholar * Gabriel K. Armijo View author publications You can also search for this author inPubMed Google Scholar * Romina

Ghale View author publications You can also search for this author inPubMed Google Scholar * Kristen Victor View author publications You can also search for this author inPubMed Google

Scholar * Brianna Gipson View author publications You can also search for this author inPubMed Google Scholar * Sebastien Monette View author publications You can also search for this author

inPubMed Google Scholar * Marco Vincenzo Russo View author publications You can also search for this author inPubMed Google Scholar * Chi L. Nguyen View author publications You can also

search for this author inPubMed Google Scholar * John Slingerland View author publications You can also search for this author inPubMed Google Scholar * Ying Taur View author publications

You can also search for this author inPubMed Google Scholar * Kate A. Markey View author publications You can also search for this author inPubMed Google Scholar * Hana Andrlova View author

publications You can also search for this author inPubMed Google Scholar * Sergio Giralt View author publications You can also search for this author inPubMed Google Scholar * Miguel-Angel

Perales View author publications You can also search for this author inPubMed Google Scholar * Pavan Reddy View author publications You can also search for this author inPubMed Google

Scholar * Jonathan U. Peled View author publications You can also search for this author inPubMed Google Scholar * Melody Smith View author publications You can also search for this author

inPubMed Google Scholar * Justin R. Cross View author publications You can also search for this author inPubMed Google Scholar * Marina Burgos da Silva View author publications You can also

search for this author inPubMed Google Scholar * Clarissa Campbell View author publications You can also search for this author inPubMed Google Scholar * Marcel R. M. van den Brink View

author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS S.L., O.M., C.C. and M.R.M.v.d.B designed the study and wrote the manuscript. S.L. and C.C.

performed harvest experiments and flow cytometric analyses. S.L. performed BM + T experiments and FXR reporter assays. O.M. selected the patient cohort and analysed human bile acid profiling

and metagenomic data. R.J.F.R. and J.R.C. quantified and analysed the LC–MS/MS bile acid profiling data and advised on study design. A.I.K. analysed the mouse RNA and human scRNA-seq data.

A.D. analysed the mouse metagenomic sequencing data. N.R.W. assisted with code resources and oversight. K.S. assisted with organizing the sequencing files and creating biorepositories. J.P.

performed human and mice in vitro T cell assays and flow cytometric analysis. T.F. performed biostatistical analysis. E.L. and P.R. performed ΔFXR recipient BM + T. J.F. assisted with the

analysis of metagenomic data. G.K.A., R.G., K.V. and B.G. assisted with BM + T experiments. S.M. carried out histopathological analyses of tissues. J.S. coordinated the faecal microbiome

collection. M.V.R., C.L.N., Y.T., K.A.M., H.A., M.B.d.S., J.U.P. and M.S. contributed to analysis strategies. S.G. and M.-A.P. contributed to clinical data collection. C.C. and M.R.M.v.d.B.

supervised the study and contributed equally. S.L. and O.M. contributed equally. All authors reviewed and approved the manuscript. CORRESPONDING AUTHORS Correspondence to Clarissa Campbell

or Marcel R. M. van den Brink. ETHICS DECLARATIONS COMPETING INTERESTS M.-A.P. reports honoraria from Adicet, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir,

Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG and Vor Biopharma; he serves on DSMBs for Cidara

Therapeutics, Medigene and Sellas Life Sciences, and the scientific advisory board of NexImmune; he has ownership interests in NexImmune and Omeros; and he has received institutional

research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics and Novartis. K.A.M. holds equity and is on the advisory board of Postbiotics Plus, and

has consulted for Incyte. J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics, and consulting fees from Da Volterra, CSL Behring and

MaaT Pharma; he serves on the Advisory board of and holds equity in Postbiotics Plus Research; and he has filed intellectual property applications related to the microbiome (reference

numbers 62/843,849, 62/977,908 and 15/756,845). M.R.M.v.d.B. has received research support and stock options from Seres Therapeutics, and stock options from Notch Therapeutics and Pluto

Therapeutics; he has received royalties from Wolters Kluwer; he has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Vor Biopharma, Rheos

Medicines, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Ceramedix, Lygenesis, Pluto Therapeutics, GlaskoSmithKline, Da Volterra, Thymofox, Garuda, Novartis (Spouse),

Synthekine (Spouse), Beigene (Spouse) and Kite (Spouse); he has IP Licensing with Seres Therapeutics and Juno Therapeutics; and he holds a fiduciary role on the Foundation Board of DKMS (a

nonprofit organization). Memorial Sloan Kettering has institutional financial interests relative to Seres Therapeutics. The remaining authors declare no competing interests. PEER REVIEW PEER

REVIEW INFORMATION _Nature Microbiology_ thanks Pieter Dorrestein, Kenya Honda and Olle Ringden for their contribution to the peer review of this work. Peer reviewer reports are available.

ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EXTENDED DATA EXTENDED DATA

FIG. 1 IMPACT OF ALLOREACTIVE T CELLS ON BA RATIOS AND CLINICAL MARKERS. Lethally irradiated 6-8 week old female BALBc mice were transplanted with 10 ×106 B6 BM cells alone (BM) or together

with 1 ×106 T cells (BM + T). BAs were quantified on day 7 post-transplant by LC-MS in the cecal contents and plasma: (A) ratio of microbe- to host-derived BAs, (B) ratio of unconjugated to

glycine- and taurine-conjugated BA and (C) estimated cecal levels of the T cell modulatory BAs 3-oxoLCA and isoLCA (below the linear range of quantification. Weight loss (D), clinical GVHD

scores (E) and cumulative food intake per mouse (F), plasma levels of AST (G), ALT (H), albumin (I), cholesterol (J), and triglycerides (K) at day 7 post-transplant of these mice. (A, B,

D-K) Data combined from two independent experiments (n = 10). (C) Data is representative of two independent experiments (n = 5). (A-K) Data shown as mean ± S.D and statistical significance

determined by two-tailed Mann-Whitney test. EXTENDED DATA FIG. 2 FXR SIGNALING IN T CELLS MODULATES GVHD. (A) Principle of the FXR luciferase reporter assay used in Fig. 3a and b and

Extended Data Fig. 2b. (B) Stably transfected HepG2 cells expressing luciferase under the control of an FXR-responsive element were treated with the indicated doses of CDCA. Luciferase units

(luminescence) were normalized to cell viability assessed by Hoechst 33342 staining (fluorescence). Data representative of two independent experiments and presented as technical triplicates

with means connected. Weight loss (C) and clinical GVHD score (D) of survival experiment shown in Fig. 3d. Data combined from three independent experiments (BM group n = 20, BM + T groups n

 = 30 per group) and means ± S.D connected. (E) Survival of cohoused WT or _nr1h4_-/-l (Δ FXR) B6 mice receiving BALBc BM + T. Data combined from three independent experiments (n = 13 per

group). Statistical significance was determined using log-rank test. (F-H) BALBc recipient mice transplanted with 10 ×106 B6 BM cells alone or together with 1 ×106 T cells from either

_Nr1h4_fl/fl (BM + TWT) or _Cd4__Cre_ _Nr1h4_fl/fl (BM + TΔFXR) mice on a C57Bl/6 N background. (F) Organ-specific and compound histopathological scores at day 28 post-transplant of

transplanted mice with representative histology images shown in (G). Data from one experiment (n = 10 per group) and statistical significance was determined by two-tailed Mann-Whitney test.

(H) Production of IFNγ by CD4+ and CD8+ T cells in the smallI and large intestine lamina propria 14 days after transplant. Data combined from two (n = 10 per group) and presented as mean ±

S.D. Statistical significance was determined by by two-tailed Mann-Whitney test. EXTENDED DATA FIG. 3 CONSORT DIAGRAM. Criteria for the cohort selection used for data shown in Figs. 4, 5 and

Extended Data Fig. 5-8. PBSC: peripheral blood stem cell graft. EXTENDED DATA FIG. 4 EFFECTS OF UDCA EXPOSURE ON THE INTESTINAL BA POOL. Data from n = 280 samples from either

peri-engraftment or peri-GVHD onset timepoints. Fecal concentrations of UDCA (A) and microbe-derived BAs (B). UDCA exposure status is shown in the x-axis (_w = weeks_; _m = months_ since

last exposure). Statistical significance determined by the 2-sided Wilcoxon Rank-sum test. The boxplot center line corresponds to the median, box limits correspond to the 25th and 75th

percentile, and whiskers correspond to 1.5x interquartile range. Correlation of fecal UDCA concentrations with the levels of conjugated UDCA (conj-UDCA, C), total BAs (D), microbe-derived

BAs (E), host-derived BAs (F), nonUDCA total BAs (G) nonUDCA microbe-derived BAs (H), and microbe- to host- derived (M/H) ratio excluding UDCA (nonUDCA, I). The solid line represents a

linear regression model fitted to the data. The shaded region surrounding the line indicates a 95% confidence interval for the regression line. Total BAs nonUDCA (G) are measured in pmol/mg.

(J,K) Correlation matrix of the BA species covarying with UDCA. (K) Showing BA species with a Pearson correlation coefficient (R > 0.4). EXTENDED DATA FIG. 5 FECAL BA PROFILES AT THE

PERI-GVHD ONSET TIME POINT. Showing the levels of total microbe-derived BAs (A), microbe- to host-derived (M/H) BA ratio (B), M*/H (_that is_, nonUDCA M/H) BA ratio (C), and the ratio of

unconjugated to amidated BAs (D). Data representative of 57 control and 58 GVHD patients. Statistical significance determined with the 2-sided Wilcoxon Rank-sum test. The boxplot center line

corresponds to the median, box limits correspond to the 25th and 75th percentile, and whiskers correspond to 1.5x interquartile range. (E-F) Differential abundance of BAs between GVHD and

controls in peri-GVHD onset samples after multivariate adjustment. (E) Grid plot showing significance status, q-values, and log fold changes of BAs relative to indicated clinical variables.

(F) Volcano plot showing log-transformed adjusted p-values vs log fold changes of BAs between GVHD and control patients. Statistical comparison was made using the two-sided empirical Bayes

moderated t-test and p-values were adjusted using the Benjamini-Hochberg method. EXTENDED DATA FIG. 6 FECAL BA PROFILES AT THE PERI-ENGRAFTMENT TIME POINT. Total BAs (A), host-derived (B),

microbe-derived (C), microbe*-derived (D), microbe-derived to host-derived (M/H) BA ratio (E), M*/H (nonUDCA M/H) BA ratio in patients that develop GVHD vs controls (F). (G) Pie chart

showing the averaged relative contributions of host-derived and microbe*-derived to the calculated total BA pool. Glycine- and taurine-conjugated (H), unconjugated (I), and sulfated (G) BAs.

Pie chart showing the averaged percentages of glycine- and taurine-conjugated, unconjugated and sulfated BAs in patients with GVHD vs controls in peri-GVHD onset samples (K).

Microbe*-derived BAs: Microbe-derived BAs excluding UDCA. Data representative of 90 control and 86 GVHD patients. The boxplot center line corresponds to the median, box limits correspond to

the 25th and 75th percentile, and whiskers correspond to 1.5x interquartile range. Statistical significance determined with the 2-sided Wilcoxon Rank-sum test. (L,M) Differential abundance

of BAs between GVHD and control patients in peri-engraftment samples after multivariate adjustment (L) Grid plot showing significance status, q-values, and log fold changes of BAs relative

to indicated clinical variables. (M) Volcano plot showing log-transformed adjusted p-values vs log fold changes of BAs between GVHD and control patients. Statistical comparison was made

using the two-sided empirical Bayes moderated t-test and p-values were adjusted using the Benjamini-Hochberg method. EXTENDED DATA FIG. 7 MICROBIOME FEATURES IN PERI-GVHD ONSET SAMPLES.

Relative abundance of (A) _Eggerthella lenta_ and (B) _Ruminococcus gnavus_. Data representative of 49 control and 46 GVHD patients (C) Correlation of the sum of _bai_ operon gene and

α-diveristy as measured by the Simpson reciprocal index. The solid line represents a linear regression model fitted to the data. The shaded region surrounding the line indicates a 95%

confidence interval for the regression line. Data representative of 82 patients with peri-GVHD onset samples. (D) α-diversity, (E) sum of _bai_ operon genes identified by shotgun metagenomic

analysis (measured in counts per million), and (F) levels of microbe-derived BAs* (pmol/mg) in patients with or without intestinal pathogen domination. Data representative of 41 patients

with and 74 patients without pathogen domination. Microbe-derived BAs*= microbe-derived BAs excluding UDCA. Statistical significance determined with the univariate 2-sided Wilcoxon Rank-sum

test. The boxplot center line corresponds to the median, box limits correspond to the 25th and 75th percentile, and whiskers correspond to 1.5x interquartile range. R correspond to Pearson’s

correlation coefficient. EXTENDED DATA FIG. 8 IN VITRO HUMAN T CELL PROLIFERATION IN RESPONSE TO FXR ACTIVATION OR INHIBITION WITH DRUGS OR BAS. (A) Experimental design. Purified human T

cells were activated with anti-CD3 and anti-CD28 antibodies in the presence of recombinant IL-2 for 2 days and further cultured either in the presence of anti-CD3/anti-CD28 antibodies and

IL-2 (continuous activation control) or in their absence (vehicle control) with or without the indicated compounds for 96 hours. Showing T cell confluence in response to CDCA and UDCA (B) or

GW4064 and DY268 (C) at the indicated concentrations. Cell viability (D, E, F) and representative histograms (G, H) showing CD25 levels determined by flow cytometric analysis. (I-L) CD25

expression in CD4+ and CD8+ T cells after 96 hours of treatment with CDCA and UDCA (I-J), or GW4064 and DY268 (K-L). Showing the geometric mean fluorescence intensity (MFI) of CD25 in CD25+

T cells. Values were normalized to the MFI of the vehicle-treated group. (M, N) Frequency of CD25 positive cells on day 4 post-activation. (O) CD25 expression from T cells of FXRWT or FXRWT

mice treated with anti-CD3 and anti-CD28 antibodies in the presence of IL-2 for 2 days before incubation with CDCA (100 nM), or UDCA (100 nM), anti-CD3, anti-CD28 and IL-2 (continuous

activation), or vehicle for 2 more days. CD25 expression was measured as geometric mean fluorescence intensity (MFI) of CD25 in CD25+ T cells normalized to the MFI of the vehicle-treated

group. Statistical analysis was performed by two-way (B,C) or one-way ANOVA followed by multiple t-test with Bonferoni correction (D-F, I-O). Each data point in (I-N) shows the average of

technical duplicates for a single donor. Bars denote the standard error of the mean. Data representative of 4 independent experiments with a total of 4 PBMC donors. Each data point in (G)

shows the average of technical triplicates from two mice. Bars denote the standard error of the mean. Data representative of 3 independent experiments with a total of 6 mice. EXTENDED DATA

FIG. 9 QUALITY CONTROL OF SINGLE CELL RNA-SEQUENCING PROFILING OF IN VITRO ACTIVATED T CELLS TREATED WITH FXR LIGANDS, DMSO OR ACTIVATING SIGNALS FOR 24 H. Visualization of 60,767 cells

using a uniform manifold approximation and projection (UMAP) of (A) cells from the two donors and (B) per hashtag before eliminating any cells. (C) Total counts (log10 scale) (D) total

genes, (E) ribosomal fraction, (F) mitochondrial fraction per cell, (G) predicted doublet and (H) doublet score. (I-K) Cells expressing markers for B and Natural Killer cells were defined as

contaminants. (L-M) UMAP and stacked plot showing the fraction of retained (33,634) and removed cells (27,133). EXTENDED DATA FIG. 10 SINGLE CELL RNA-SEQUENCING PROFILING OF IN VITRO

ACTIVATED T CELLS TREATED WITH CDCA (100 NM), UDCA (100 NM), GW4064 (1UM) AND DY268 (1UM) FOR 24 H. (A) Gene markers used to identify cell populations. Visualization of annotated cells using

a uniform manifold approximation and projection (UMAP) of (B) subtypes after batch correction and (C) per treatment arm. (D) Gene Set Enrichment Analysis of pathways differentially

regulated in the different conditions (CDCA 100 nM, UDCA 100 nM, GW4064 1uM, DY268 1uM) relative to the vehicle control in CD4+, CD8+ and regulatory T cell populations. Displaying

significant pathways. SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION Dot plot for metabolomics in mice, gating strategy and Supplementary Tables 1–9. REPORTING SUMMARY PEER REVIEW FILE

SUPPLEMENTARY TABLE Bulk RNA-sequencing of liver, small and large intestine; source data for extended data figures; ASV sequences; antibody dilutions. SOURCE DATA SOURCE DATA FIG. 1 BA

levels in mice with GVHD vs controls SOURCE DATA FIG. 2 Abundance of BA-related genes and results of bulk RNA-sequencing of liver tissue and epithelial fractions of the small and large

intestines in mice with GVHD vs controls. SOURCE DATA FIG. 3 Transcriptional activity of FXR in response to treatment with individual bile acids; survival outcomes associated with enhanced

FXR activity and FXR knockout (KO) conditions. SOURCE DATA FIG. 4 Information on the cohort (GVHD vs controls), the concentrations/AUC of BAs, BA family. SOURCE DATA FIG. 5 Abundance of

BA-related genes, α-diversity, ASV counts used for the composition plot. SOURCE DATA FIG. 6 T cell confluence in response to different treatment arms; CD25 MFI in response to different

treatment arms; source data for fold-change plots in CD4 T cells. RIGHTS AND PERMISSIONS Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this

article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of

such publishing agreement and applicable law. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Lindner, S., Miltiadous, O., Ramos, R.J.F. _et al._ Altered microbial bile acid

metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. _Nat Microbiol_ 9, 614–630 (2024). https://doi.org/10.1038/s41564-024-01617-w Download citation *

Received: 28 January 2023 * Accepted: 22 January 2024 * Published: 01 March 2024 * Issue Date: March 2024 * DOI: https://doi.org/10.1038/s41564-024-01617-w SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative